The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview;Wirksamkeit von atomoxetin bei kindern, jugendlichen und erwachsenen mit ADHS: Eine systematische übersicht

Nervenarzt

Volumn 77, Issue 3, 2006, Pages 294-308

  Sevecke, K ^a   Battel, S ^a   Dittmann, R ^b   Lehmkuhl, G ^a   Dopfner M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ADHD; Adverse events; Atomoxetine; Efficacy; Pharmacotherapy

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR;

ABDOMINAL DISEASE; ANOREXIA; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; REVIEW; SYSTEMATIC REVIEW; VERTIGO;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPYLAMINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645224925     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-005-1970-1     Document Type: Review

References (34)

1. Adam C, Döpfner M, Lehmkuhl G (2002) Der Verlauf von Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS) im Jugend- und Erwachsenenalter. Kindheit und Entwicklung 11:73-81
2. Adler L, Spencer T, Michelson D et al. (2003) Long-term treatment effects of atomoxetine in adults with attention-deficit/hyperactivity disorder (AD-HD). Abstractbd. 458. Poster ECNP, Prag
3. Adler L, Spencer T, Reimherr F et al. (2003) Efficacy and safety of atomoxetine in long-term open label treatment of adults with ADHD. Abstractbd. 241. Poster American Pediatric Academy (APA), San Francisco
4. Adler L, Spencer T, Sutton V et al. (2003) Dose and time response of atomoxetine use in adult ADHD. Poster American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband:112-113
5. Allen AJ, Milton D, Michelson D et al. (2003) Efficacy of atomoxetine treatment for adolescents with attention-deficit/hyperactivity disorder. Poster American Pediatric Academy (APA), San Francisco, Abstractband:240-241
6. Banaschewski T, Roessner V, Dittmann RW et al. (2004) Non-stimulant medications in the treatment of ADHD. Eur J Child Adolesc Psychiatry (in press)
7. Biedermann J, Heiligenstein JH, Faries DE et al. (2002) Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/ hyperactivity disorder. Pediatrics 6:1-7
8. Brown WJ, Wernicke J, Allen AJ et al. (2002) Efficacy of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Poster American Pediatric Academy (APA), Philadelphia
9. Bymaster FP, Katner JS, Nelson DL et al. (2002) Atomoxetin increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
10. Döpfner M, Frölich J, Lehmkuhl G (2000) Hyperkinetische Störungen. Leitfaden Kinder- und Jugendpsychotherapie. Hogrefe, Göttingen
11. Döpfner M, Lehmkuhl G (2002) Evidenzbasierte Therapie von Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). Prax Kinderpsychol Kinderpsychiatr 51:419-440
12. Fachinformation Atomoxetin, Stand 2005
13. Garland EJ (1998) Pharmacotherapy od adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 12:385-395
14. Heil SH, Holmes HW, Bickel WK et al. (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156
15. Kratochvil C, Newcorn J, Gao H et al. (2003) Atomoxetine for comorbid ADHD and affective symptoms. Poster American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband:160
16. Kratochvil ChJ, Heiligenstein JH, Dittmann R et al. (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776-784
17. Kratochvil CJ, Milton D, Vaughan B et al. (2003) Atomoxetine in the treatment of young children with ADHD. Poster American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband:147
18. Mc Cracken JT, Sallee FR, Leonard HL et al. (2003) Improvement of ADHD by atomoxetine in children with tic disorders. Poster American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband:117
19. Michelson D, Adler L, Spencer T et al. (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. World J Biol Psychiatry 53:112-120
20. Michelson D, Allen AJ, Busner J et al. (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperacitivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
21. Michelson D, Buitelaar J, Danckaerts M et al. (2003) Results from a long-term trial of atomoxetine in the prevention of relapse in ADHD. Eur J Child Adolesc Psychiatry 12:142
22. Michelson D, Faries D, Wernicke J et al. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 5:1-9
23. Perwin AR, Faries D, Kratochvil C (2003) Long-term effects of atomoxetine on health-related quality of life. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband:168
24. Sevecke K, Döpfner M, Lehmkuhl G (2004) Die Wirksamkeit von Stimulanzien-Retardpräparaten bei Kindern und Jugendlichen mit ADHD-eine systematische Übersicht. Z Kinder Jugendpsychiatr Psychother 32(40): 265-278
25. Spencer T, Biederman J, Wilens T et al. (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432
26. Spencer T, Biederman J, Wilens T et al. (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
27. Spencer T, Biedermann J, Heiligenstein J et al. (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 3:251-265
28. Spencer T, Heiligenstein MD, Biedermann J et al. (2002) Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 12:1140-1147
29. Spencer TJ, Ruff DR, Feldman PD et al. (2003) Long-term effects of atomoxetine on growth in children and adolescents with ADHD. Poster American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband:170
30. Weiss M, Tannock R, Krachtovil C et al. (2003) Placebo-controlled study of once-daily atomoxetine in the school setting. Eur J Child Adolesc Psychiatry 12:143
31. Wender PH, Reimherr FW, Wood D et al. (1985) A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 142:547-552
32. Wenicke JF, Kratochvil C, Milton D et al. (2002) Long-term safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Poster American Pediatric Academy (APA), Philadelphia
33. Wernicke JF, Faries D, Girod D et al. (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729-740
34. Wernicke JF, Kratochvil ChJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63:50-55